Croma-pharma Gesellschaft M.b.h.

Croma Pharma Gmbh

Mucobiomer Biotechnologische Forschungs- Und Entwicklungs Gesmbh

Croma-pharma Gesellchaft M.b.h.

Martin Prinz

Ralph Hollaus

Robert Sachsenhofer

Martin Hoffer

Sonja Höller

Sonja HÖLLER

A sterile hydrogel composition that includes a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 μmol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 μmol per gram polymer, and wherein the thiol-modified hyaluronan has a mean molecular weight of at least 400 kDa.

Hydrogel composition comprising a crosslinked polymer

A sterile hydrogel composition comprising a crosslinked polymer, wherein the crosslinked polymer is an oxidation product of a thiol-modified hyaluronan and wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of more than about 80 μmol per gram polymer, wherein the thiol-modified hyaluronan has a degree of modification of hyaluronan with thiol moieties of less than about 280 μmol per gram polymer, wherein the composition has a residual thiol content of less than 20% in respect to the degree of modification of the thiol-modified hyaluronan.

The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.

Hydrogen sulfide releasing polymer compounds

The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 &#x3bc;mol/g polymer to 280 &#x3bc;mol/g polymer, for the specific use in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms wherein said solution is applied prior to sleep.

Therapeutic use of a sterile aqueous ophthalmic solution

A method of preventing or treating an eye condition includes administering a sterile aqueous ophthalmic solution to an eye for the prevention or treatment of dry eye syndrome or dry eye sign and/or dry eye symptom. The sterile aqueous ophthalmic solution includes about 0.05% to about 0.5% (w/w) of N&#x2014;(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N&#x2014;(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 &#x3bc;mol/g polymer to 280 &#x3bc;mol/g polymer.

Method for treating dry eye syndrome

The present invention relates to a sterile aqueous ophthalmic solution comprising N&#x2014;(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N&#x2014;(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 &#x3bc;mol/g polymer to 280 &#x3bc;mol/g polymer, for use in the treatment of corneal wounds.

Handle for a cannula

The present invention is concerned with a sterile aqueous ophthalmic solution comprising about 0.05% to about 0.5% (w/w) of N&#x2014;(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N&#x2014;(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 &#x3bc;mol/g polymer to 280 &#x3bc;mol/g polymer. The invention is also concerned with a container containing said ophthalmic solution as well as the use thereof in the prevention or treatment of dry eye syndrome or dry eye signs and/or symptoms.

Aqueous ophthalmic solution and method for treating dry eye syndrome

By the reaction of chitosan with iminothiolactones such as 2-iminothiolane, thiol groups can be covalently immobilized on the polymer. The resulting chitosan derivatives exhibit thiol groups which are capable of forming inter- and intramolecular disulfide bonds. Because of this crosslinking process the viscosity of polymer solutions is strongly improved. Moreover, the cationic character of the polymer is strongly improved. Preferred applications of these novel chitosan derivatives are their cosmetic and pharmaceutical use 

Growing community of inventors

Leobendorf, Austria

Martin Prinz